<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01775423</url>
  </required_header>
  <id_info>
    <org_study_id>BBI608-101</org_study_id>
    <nct_id>NCT01775423</nct_id>
  </id_info>
  <brief_title>A Study of BBI608 in Adult Patients With Advanced Malignancies</brief_title>
  <official_title>A Phase I Clinical Study of BBI608 in Adult Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sumitomo Dainippon Pharma Oncology, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sumitomo Dainippon Pharma Oncology, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, single arm, dose escalation study of BBI608 in patients with advanced&#xD;
      malignancies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">August 6, 2015</completion_date>
  <primary_completion_date type="Actual">August 6, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Adverse events will be assessed at baseline, while the participant is taking BBI608, and for 30 days after stopping therapy. The average length of this duration is expected to be approximately 4 months.</time_frame>
    <description>Assessment of safety of BBI608 given in monotherapy to patients with advanced malignancies by reporting of adverse events and serious adverse events</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Cancer, Advanced Malignancies</condition>
  <arm_group>
    <arm_group_label>BBI608</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BBI608</intervention_name>
    <arm_group_label>BBI608</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Signed written informed consent must be obtained and documented according to&#xD;
             International Conference on Harmonisation (ICH)- Good Clinical Practice (GCP), the&#xD;
             local regulatory requirements, and permission to use private health information in&#xD;
             accordance with the Health Insurance Portability and Accountability Act (HIPPA) prior&#xD;
             to study-specific screening procedures&#xD;
&#xD;
          2. For solid tumors or lymphoma, a histologically or cytologically confirmed solid tumor&#xD;
             that is metastatic, unresectable, or recurrent and for which standard curative or&#xD;
             palliative therapies do not exist or are no longer effective.&#xD;
&#xD;
          3. ≥ 18 years of age&#xD;
&#xD;
          4. For solid tumors, measurable disease as defined by Response Evaluation Criteria in&#xD;
             Solid Tumors (RECIST 1.1)&#xD;
&#xD;
          5. For lymphoma, measurable disease as defined by the International Workshop to&#xD;
             Standardize Response Criteria for Non-Hodgkin's Lymphoma&#xD;
&#xD;
          6. For multiple myeloma, measurable disease as defined by the International Uniform&#xD;
             Response Criteria for Multiple Myeloma&#xD;
&#xD;
          7. Karnofsky performance status greater than or equal to 70%&#xD;
&#xD;
          8. Male or female patients of child-producing potential must agree to use contraception&#xD;
             or avoidance of pregnancy measures during the study and for 30 days after the last&#xD;
             BBI608 dose&#xD;
&#xD;
          9. Females of childbearing potential must have a negative serum pregnancy test&#xD;
&#xD;
         10. Aspartate transaminase (AST) and alanine transaminase (ALT) less than or equal to 1.5&#xD;
             × upper limit of normal(ULN)&#xD;
&#xD;
         11. Hemoglobin (Hgb) greater than or equal to 10 g/dl&#xD;
&#xD;
         12. Total bilirubin less than or equal to 1.5 × ULN&#xD;
&#xD;
         13. Creatinine less than or equal to 1.5 x ULN or creatinine clearance greater than 60&#xD;
             mL/min/1.73 m2 for patients with creatinine levels above institutional normal.&#xD;
             Creatinine &lt; 2.5 x ULN for multiple myeloma patients.&#xD;
&#xD;
         14. Absolute neutrophil count greater than or equal to 1.5 x 109/L&#xD;
&#xD;
         15. Platelets greater than or equal to 100 x 109/L&#xD;
&#xD;
         16. Life expectancy greater than or equal to 3 months&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents&#xD;
             within four weeks of first dose with the exception for a single dose radiation up to 8&#xD;
             Gray (equal to 800 RAD) with palliative intent for pain control up to 14 days before&#xD;
             beginning the administration of BBI608.&#xD;
&#xD;
          2. Surgery within 4 weeks prior to first dose&#xD;
&#xD;
          3. Any known untreated brain metastases. Treated subjects must be stable for 4 weeks&#xD;
             after completion of that treatment, with image documentation required. Patients must&#xD;
             have no clinical symptoms from brain metastases and must be either off steroids or on&#xD;
             a stable dose of steroids for at least 2 weeks prior to protocol enrollment. Patients&#xD;
             with known leptomeningeal metastases are excluded, even if treated.&#xD;
&#xD;
          4. Pregnant or breastfeeding&#xD;
&#xD;
          5. Significant gastrointestinal disorder(s), in the opinion of the Principal&#xD;
             Investigator, (e.g., Crohn's disease, ulcerative colitis, extensive gastric and small&#xD;
             intestine resection)&#xD;
&#xD;
          6. Unable or unwilling to swallow BBI608 capsules daily&#xD;
&#xD;
          7. Uncontrolled intercurrent illness including, but not limited to ongoing or active&#xD;
             infection, clinically significant non-healing or healing wounds, symptomatic&#xD;
             congestive heart failure, unstable angina pectoris, cardiac arrhythmia, significant&#xD;
             pulmonary disease (shortness of breath at rest or mild exertion), uncontrolled&#xD;
             infection or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institute for Translational Oncology Research, Greenville Hospital System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Cancer Center</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 17, 2013</study_first_submitted>
  <study_first_submitted_qc>January 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2013</study_first_posted>
  <last_update_submitted>January 22, 2021</last_update_submitted>
  <last_update_submitted_qc>January 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

